RhumbLine Advisers
CMPX icon

RhumbLine Advisers’s Compass Therapeutics CMPX Stock Holding History

RhumbLine Advisers’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
158,444
+11,428
+8% +$33.7K ﹤0.01% 2983
2026
Q1 		$778K Buy
147,016
+12,411
+9% +$71.6K ﹤0.01% 2332
2025
Q4 		$723K Sell
134,605
-4,708
-3% -$21.7K ﹤0.01% 2420
2025
Q3 		$488K Buy
139,313
+25,826
+23% +$81.6K ﹤0.01% 2717
2025
Q2 		$295K Sell
113,487
-6,542
-5% -$13.5K ﹤0.01% 2997
2025
Q1 		$228K Sell
120,029
-9,087
-7% -$24.2K ﹤0.01% 3043
2024
Q4 		$187K Buy
129,116
+3,822
+3% +$6.35K ﹤0.01% 3229
2024
Q3 		$231K Sell
125,294
-6,495
-5% -$8.1K ﹤0.01% 3164
2024
Q2 		$132K Buy
131,789
+12,315
+10% +$18K ﹤0.01% 3425
2024
Q1 		$237K Buy
119,474
+2,942
+3% +$5.08K ﹤0.01% 3096
2023
Q4 		$182K Sell
116,532
-587
-0.5% -$1.02K ﹤0.01% 3229
2023
Q3 		$231K Buy
117,119
+4,791
+4% +$11.8K ﹤0.01% 3078
2023
Q2 		$357K Buy
+112,328
New +$353K ﹤0.01% 2896

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's CMPX Position: Q2 2026 in Review

RhumbLine Advisers increased its Compass Therapeutics (CMPX) stake by 7.8% in Q2 2026, buying an estimated $33.7K and bringing the position to 158,444 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #2983.

RhumbLine Advisers first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. The position peaked at $778K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • RhumbLine Advisers held 158,444 shares of Compass Therapeutics worth $347K as of Q2 2026.
  • RhumbLine Advisers bought 11,428 Compass Therapeutics shares in Q2 2026, an estimated $33.7K.
  • Compass Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2983 holding.
  • RhumbLine Advisers first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Compass Therapeutics position peaked at $778K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.